Merch
Medical card
Clinicians are moving past the abstinence-or-endorsement binary, building new frameworks for clients who use cannabis for anxiety, depression, and PTSD.
A client sits down in a therapist’s office and mentions, almost in passing, that they’ve been using cannabis for sleep. The therapist pauses. A decade ago, many clinicians would have steered the conversation toward cessation. Today, a growing number of mental health professionals are choosing a different path: asking how, asking why, and working with the client’s cannabis use rather than against it.
That shift reflects a broader reckoning about cannabis and therapy across mental health practice. Cannabis use among therapy clients has become common enough that clinicians who avoid the topic risk missing information that shapes treatment. A 2024 survey in Harm Reduction Journal found that in nearly 28% of healthcare encounters, cannabis use is never discussed. Providers initiated the conversation only 15% of the time. Anticipated cannabis stigma in healthcare settings, both from patients and providers, drove much of the silence.
Why Clients Use Cannabis Before Therapy, and What the Data Shows
Large-scale data confirms that cannabis self-medication for mental health symptoms is common. The International Cannabis Policy Study, covering more than 27,000 respondents in the U.S. and Canada, found that 52% of medical cannabis users cited anxiety as a reason, and 40% cited depression. These aren’t fringe motivations; they represent the primary drivers of self-directed cannabis use.
A 2025 study in BMJ Mental Health added a critical layer. Researchers surveyed 3,389 cannabis users and found that those who started using cannabis to self-medicate reported higher weekly THC consumption and elevated levels of paranoia, anxiety, and depression compared to recreational-origin users. Most self-medicators scored above clinical referral thresholds for depression and anxiety. The finding is cross-sectional, so it can’t establish that self-medication caused the worsening. It does signal that clients who say they use cannabis “for anxiety” may carry unmet treatment needs the therapist should address.
How Therapists Are Integrating Cannabis and Therapy Through Harm Reduction
A cohort of therapists has moved beyond the abstinence-or-endorsement binary and into cannabis harm reduction. The American Counseling Association’s Counseling Today documented how practitioners are using motivational interviewing, decision-making matrices, and collaborative goal-setting to address cannabis use without requiring clients to stop. Clinicians working in this model report that nonjudgmental engagement, including avoiding terms like “addiction” at first contact, preserves the therapeutic alliance and keeps clients from shutting down.
The evidence base for substance use counseling supports this measured approach. A Cochrane Review of 23 randomized controlled trials on cannabis use disorder found that motivational enhancement therapy (MET) combined with cognitive-behavioral therapy (CBT) and abstinence-based incentives had the most consistent support for reducing cannabis use frequency and dependence severity in the short term. No approach showed durable effectiveness past nine months. For therapists, that means framing treatment goals around ongoing engagement rather than one-time cessation.
Cannabis-informed practice (discussing and contextualizing a client’s use) and cannabis-assisted psychotherapy (incorporating cannabis into sessions as a therapeutic tool) are distinct clinical approaches. Most therapists adopting harm reduction frameworks operate in the former category.
Cannabis and Therapy for PTSD: Challenging a Clinical Assumption
Many therapists have been trained to view concurrent cannabis use as a barrier to trauma-focused therapy. A 2024 meta-analysis in the Journal of Anxiety Disorders, drawing on individual patient data from four RCTs within the Project Harmony dataset, challenged that assumption. Researchers found that baseline cannabis use did not significantly impair outcomes for people receiving trauma-focused or non-trauma-focused therapy for co-occurring PTSD and substance use disorders. For clinicians considering whether to require abstinence before beginning PTSD treatment, this data may support a more flexible approach.
Cannabis-Assisted Psychotherapy: The Emerging Clinical Model
At the furthest edge of this spectrum, a small number of clinicians are testing cannabis as a therapeutic tool within structured sessions. A 2023 case report in Frontiers in Psychiatry described a patient with complex dissociative PTSD who underwent 10 sessions of cannabis-assisted psychotherapy using psychedelic somatic interactional psychotherapy, paired with integrative CBT. The patient showed a 98.5% reduction in pathological dissociation, sustained at two-year follow-up. This is a single case report, the weakest tier of clinical evidence, and no randomized controlled trials have been conducted on cannabis-assisted psychotherapy. Practitioners who offer it draw parallels to the psychedelic therapy framework: preparation, dosing, integration.
The Cannabis Education Gap in Mental Health Training
Most mental health professionals received no education on cannabis and mental health during their training. A 2021 survey of physicians in the Society of Cannabis Clinicians found that only about half felt sufficient information existed to practice cannabis medicine, with dosing and treatment planning as the largest gaps. No major counseling or psychology licensure body has established mandatory clinical cannabis education requirements.
A 2021 qualitative study of social workers, nurses, and psychotherapists explored how mental health professionals perceive cannabis-related risks when working with cannabis-using clients, finding wide variation in clinical confidence and risk assessment frameworks. Meanwhile, the biological context continues to develop. A 2023 review in Brain Sciences surveyed the endocannabinoid system’s role in anxiety and depression and concluded that while preclinical evidence supports the plausibility of cannabinoid-based interventions, clinical evidence remains weak and low-quality.
Individual practitioners are building approaches case by case, without comprehensive guidance from their professional bodies. The tension is productive: clinicians who engage with cannabis as a clinical variable, rather than ignoring it or defaulting to prohibition, can serve their clients with greater precision. The evidence to guide that engagement is growing, if unevenly. For therapists and clients alike, the conversation about cannabis and therapy may be the most important intervention available right now.
Frequently Asked Questions
Should I tell my therapist I use cannabis?
Yes. Therapists need accurate information about all substances you use to provide effective care. Research shows that stigma is the primary barrier to disclosure, but therapists who practice within harm reduction frameworks discuss cannabis use without judgment. If your therapist responds with bias, that’s useful information about the therapeutic fit.
Does cannabis use interfere with therapy for PTSD?
Based on a 2024 meta-analysis of randomized controlled trial data, baseline cannabis use did not significantly impair outcomes for people receiving trauma-focused therapy for co-occurring PTSD and substance use disorders. This challenges a longstanding clinical assumption, though individual responses vary and concurrent substance use should be discussed with your provider.
What is cannabis-assisted psychotherapy?
Cannabis-assisted psychotherapy (CAP) is an emerging therapeutic model in which a clinician incorporates cannabis into structured psychotherapy sessions, following a preparation-dosing-integration framework similar to psychedelic-assisted therapy. CAP remains in its earliest stages, with only case reports published and no randomized controlled trials completed.
What therapy approaches have the most evidence for cannabis use disorder?
A Cochrane Review of 23 randomized controlled trials found that the combination of motivational enhancement therapy (MET) and cognitive-behavioral therapy (CBT), paired with abstinence-based incentives, had the most consistent evidence for reducing cannabis use frequency and dependence severity in the short term. No single approach showed durable effectiveness beyond nine months.
What is the difference between cannabis-informed therapy and cannabis-assisted psychotherapy?
Cannabis-informed therapy means a clinician discusses and contextualizes a client’s existing cannabis use within their treatment plan, without incorporating cannabis into sessions. Cannabis-assisted psychotherapy (CAP) uses cannabis as a therapeutic tool during structured sessions, following a preparation-dosing-integration model. Most therapists working within harm reduction frameworks practice cannabis-informed therapy. CAP remains in early-stage development with no randomized controlled trials completed.
Sign up for bi-weekly updates, packed full of cannabis education, recipes, and tips. Your inbox will love it.
